Ownership and insider activity for Moderna, Inc. (MRNA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets.
Price
| Price | $203.21 |
| Market Cap | $80.6B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-15 | Hoge Stephen | M-Exempt | 76,452 | $933K |
| 2026-09-14 | Hoge Stephen | M-Exempt | 76,453 | $933K |
| 2026-09-15 | Hoge Stephen | S-Sale | 40,281 | $5.9M |
| 2026-09-14 | Hoge Stephen | S-Sale | 40,294 | $5.8M |
| 2026-09-14 | Hoge Stephen | M-Exempt | 76,453 | $933K |
| 2026-09-15 | Hoge Stephen | M-Exempt | 76,452 | $933K |
| 2026-09-10 | Mock James M | M-Exempt | 19,836 | $614K |
| 2026-09-10 | Mock James M | S-Sale | 19,836 | $2.7M |
| 2026-09-10 | Mock James M | S-Sale | 15,000 | $2.0M |
| 2026-09-10 | Mock James M | M-Exempt | 19,836 | $614K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.1M | $134.9M | $658.4M | $235.9M | $2.62B | $6.85B | $3.21B | $2.91B | $1.93B | $2.60B |
| Short-term Investments | $1.01B | $621.2M | $863.1M | $867.1M | $1.98B | $3.88B | $6.70B | $5.70B | $5.10B | $3.20B |
| Receivables | $18.0M | $18.4M | $30.6M | $16.3M | $1.41B | $3.32B | $1.69B | $1.08B | $592.0M | $284.0M |
| Inventory | 0 | 0 | 0 | 0 | $47.0M | $1.44B | $949.0M | $202.0M | $117.0M | $153.0M |
| Total Current Assets | $1.09B | $783.2M | $1.56B | $1.13B | $6.30B | $16.07B | $13.43B | $10.32B | $8.10B | $6.54B |
| Property, Plant & Equipment | $81.2M | $139.0M | $212.0M | $287.9M | $387.0M | $1.38B | $2.14B | $2.66B | $2.96B | $2.85B |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $52.0M | $52.0M | $52.0M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $44.0M | $40.0M | $45.0M |
| Total Assets | $1.42B | $1.08B | $1.96B | $1.59B | $7.34B | $24.67B | $25.86B | $18.43B | $14.14B | $12.34B |
| Accounts Payable | $28.2M | $20.7M | $31.2M | $7.1M | $18.0M | $302.0M | $487.0M | $520.0M | $405.0M | $317.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $162.8M | $191.5M | $222.8M | $143.1M | $4.39B | $9.13B | $4.92B | $3.02B | $2.21B | $1.99B |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.24B |
| Total Liabilities | $575.3M | $459.2M | $431.9M | $414.6M | $4.78B | $10.52B | $6.74B | $4.57B | $3.24B | $3.69B |
| Retained Earnings | -$365.7M | -$621.9M | -$1.01B | -$1.50B | -$2.24B | $9.96B | $18.32B | $13.61B | $10.04B | $7.22B |
| Total Equity | $841.9M | $625.3M | $1.53B | $1.17B | $2.56B | $14.14B | $19.12B | $13.85B | $10.90B | $8.65B |
| Total Debt | $12.5M | $15.7M | $33.5M | $132.4M | $237.0M | $916.0M | $1.20B | $1.24B | $747.0M | $1.92B |
| Net Debt | -$1.05B | -$740.3M | -$1.49B | -$970.6M | -$4.37B | -$9.81B | -$8.70B | -$7.36B | -$6.28B | -$3.88B |
| Working Capital | $924.4M | $591.8M | $1.34B | $985.7M | $1.91B | $6.94B | $8.51B | $7.31B | $5.89B | $4.56B |
Financial Health
| Debt / Equity | 0.19 |
| Current Ratio | 2.29 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 2.46 |
Profitability
| Return on Equity | -39.20% |
| Return on Invested Capital | -39.16% |
| Return on Assets | -28.75% |
| Gross Margin | -12.57% |
| Operating Margin | -149.01% |
| Net Margin | -141.43% |
Related companies: BBIO · BMRN · CAI · EXEL · HALO · JAZZ · MDGL
Explore sector: Healthcare · Biotechnology
More sections of MRNA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks